1 Min Read
April 25 (Reuters) - GlaxoSmithKline:
* CFO SAYS EXPECTING SHINGRIX SALES FOR YEAR TO BE AT THE SAME RATE AS IN Q1, OR 400 MILLION STG+ FOR 2018 Further company coverage: (Reporting by UK bureau)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.